Aptorum Group Ltd (APM)Healthcare | Biotechnology | Princeton, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 11:43 a.m. UTC
The immediate outlook is severely clouded by a catastrophic collapse in share price, which has erased over 98% of the company's value over the last year. While the recent reverse stock split and regulatory compliance offer temporary relief, the underlying business fundamentals are in freefall, characterized by negative earnings, negative free cash flow, and a balance sheet where debt nearly equals total cash. The market has effectively priced out any hope of a turnaround, leaving the stock with no meaningful catalyst for recovery in the near term. Furthermore, the biotechnology sector is inherently volatile, and this specific security lacks the liquidity and stability required for a short-term trade, making it a dangerous speculative vehicle rather than an investment opportunity. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.049 |
| Market Cap | 570,062 |
| Forward P/E | -0.99 |
| Beta | 0.17 |
| Website | https://www.aptorumgroup.com |
| Date | Dividend | Yield % |
|---|---|---|
| 2026-07-20 | NaN | NaN |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.48404908 |
| Address1 | 116 Village Boulevard |
| Address2 | Suite 200 |
| All Time High | 3,328.0 |
| All Time Low | 4.6 |
| Ask | 0.8277 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 416,058 |
| Average Volume | 81,270 |
| Average Volume10Days | 416,058 |
| Beta | 0.166 |
| Bid | 0.504 |
| Bid Size | 100 |
| Book Value | 28.384 |
| City | Princeton |
| Country | United States |
| Currency | USD |
| Current Price | 0.7 |
| Current Ratio | 0.782 |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.74 |
| Day Low | 0.6 |
| Debt To Equity | 25.049 |
| Ebitda | -1,562,482 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.401 |
| Enterprise Value | -2,189,644 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 8.64016 |
| Fifty Two Week High | 44.7 |
| Fifty Two Week Low | 0.6 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 535,932 |
| Forward Eps | -0.71 |
| Forward P E | -0.9859155 |
| Free Cashflow | -1,097,453 |
| Full Time Employees | 1 |
| Fullday Change | 0.7 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Implied Shares Outstanding | 814,375 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,784,505,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. |
| Long Name | Aptorum Group Ltd |
| Market Cap | 570,062 |
| Max Age | 86,400 |
| Message Board Id | finmb_254483578 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,363,270 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,283,901 |
| Open | 0.7006 |
| Operating Cashflow | -1,836,546 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 609 951 2222 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | 0.02466178 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.752 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 0.74 |
| Regular Market Day Low | 0.6 |
| Regular Market Open | 0.7006 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 195,145 |
| Return On Assets | -0.06524 |
| Return On Equity | -0.10786 |
| Sand P52 Week Change | 0.14606059 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 634,682 |
| Shares Percent Shares Out | 0.0077 |
| Shares Short | 6,249 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 248 |
| Short Name | Aptorum Group Limited |
| Short Percent Of Float | 0.0107 |
| Short Ratio | 0.19 |
| State | NJ |
| Symbol | APM |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 3,452,891 |
| Total Cash Per Share | 4.24 |
| Total Debt | 3,442,928 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -1.9 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 10.01643 |
| Underlying Symbol | APM |
| Uuid | 4d5340b6-46d9-323c-9b3b-df42182658d0 |
| Volume | 195,145 |
| Website | https://www.aptorumgroup.com |
| Zip | 8,540 |